Skip to main content
Clinical Trials/NCT04544345
NCT04544345
Completed
Not Applicable

Impact of Atrio-ventricular Optimization With His Bundle Pacing on Treatment of Atrio-ventricular Dromotropathy

University Medical Centre Ljubljana1 site in 1 country17 target enrollmentDecember 23, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrioventricular Block
Sponsor
University Medical Centre Ljubljana
Enrollment
17
Locations
1
Primary Endpoint
Changes in left ventricular stroke volume
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study aims to determine the clinical and hemodynamic benefit of atrio-ventricular (AV) resynchronization with His bundle pacing in patients with symptomatic first degree AV block.

Detailed Description

The term AV dyssynchrony was introduced by Salden F. and coauthors in 2018. It stands for the adverse effects of AV dyssynchrony due to PR interval prolongation. According to the ESC and ACC guidelines, severe first degree AV block is an IIa indication for permanent pacemaker implantation, yet data on these patients' clinical outcomes are scarce. To independently determine the impact of AV resynchronization, His bundle pacing will be used to avoid intraventricular desynchronization. Symptomatic patients with severe first-degree AV block and echocardiographically proven AV dyssynchrony will be included in the study. All patients will receive a dual-chamber pacemaker with an atrial lead positioned in the right atrium and ventricular lead placed on the bundle of His. In a single-blind cross-over design, patients will be randomized to AV sequential His bundle pacing with echo-guided AV optimization or back-up VVI pacing mode. Each study period will last for three months. At the end of both periods, cardiopulmonary exercise testing, complete echocardiographic study, and clinical evaluation will be performed. Peak oxygen uptake and echocardiography-based hemodynamic parameters in both periods will be compared.

Registry
clinicaltrials.gov
Start Date
December 23, 2019
End Date
January 4, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Anja Zupan Mežnar

Principal Investigator

University Medical Centre Ljubljana

Eligibility Criteria

Inclusion Criteria

  • First OR second degree Mobitz type 1 atrioventricular block with a PR interval \> 250 ms
  • left ventricular ejection fraction \> 50%
  • echocardiographic criteria of atrioventricular dyssynchrony (diastolic filling time/RR interval ratio \< 0,4 OR fusion of E and A waves OR diastolic mitral regurgitation)
  • symptoms on exertion (dyspnea, palpitations)
  • insufficient shortening of PR interval during exercise (PR interval \> 200 ms at heart rate of 100 beats per minute)

Exclusion Criteria

  • left ventricular ejection fraction \< 50%
  • third degree atrioventricular block
  • atrial fibrillation
  • sinus node disease
  • left bundle branch block
  • right bundle branch block
  • ventricular arrhythmia that indicates implantation of cardioverter defibrillator
  • consumption of drugs that influence atrioventricular conduction
  • active bacterial infection
  • inability to undergo cardiopulmonary exercise test

Outcomes

Primary Outcomes

Changes in left ventricular stroke volume

Time Frame: Baseline, 3 months, 6 months

Measured by echocardiography

Changes in quality of life using the 5 level EQ-5D questionnaire

Time Frame: Baseline, 3 months, 6 months

EQ-5D is a standardized measure of health status consisting of 2 pages - the EQ-5D descriptive system (descriptive system with five levels) and the EQ visual analog scale ranging from 0 (worst state) to 100 (best state).

Changes in exercise capacity

Time Frame: Baseline, 3 months, 6 months

Measured by peak oxygen consumption on cardiopulmonary exercise test

Secondary Outcomes

  • Changes in left atrial volume(Baseline, 3 months, 6 months)
  • Changes in left ventricular volume(Baseline, 3 months, 6 months)
  • Changes in the measure of left ventricular mechanical dyssynchrony(Baseline, 3 months, 6 months)
  • Changes in lead impedance(Baseline, 3 months, 6 months)
  • Fluoroscopy time(Baseline)
  • Changes in sensing of R wave(Baseline, 3 months, 6 months)
  • Adverse events(through study completion, an average of one year)
  • Changes in QRS complex width(Baseline, 3 months, 6 months)
  • Changes in pacing thresholds(Baseline, 3 months, 6 months)

Study Sites (1)

Loading locations...

Similar Trials